Forsyth B, Fehnel SE, Danchenko N, Franois C, Brevig T. Assessing impacts of major depressive disorder (MDD) on cognitive function. Value Health. 2012 Nov 1;15(7):A341.
Forsyth B, Fehnel SE, Danchenko N, François C, Brevig T. Assessing impacts of major depressive disorder on depression. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 1, 2012. Berlin, Germany.
Carson R, Nelson LM, Williams VS, Fehnel SE, Tourkodimitris S, Baird M, et al a. Psychometric evaluation of patient-reported outcome measures for assessing ibs-c symptom severity and change: results from 2 randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 1, 2012.
Carson R, Baird M, Coon C, Fehnel SE, MacDougall J, Nelson LM. Psychometric evaluation of patient-reported outcome measures assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Presented at the ISOQOL 19th Annual Conference; October 1, 2012.
Nelson LM, Williams VS, Carson R, Baird M, Coon C, Fehnel SE. Factor analyses of chronic constipation patient-reported outcome measures: results from phase 2b and phase 3 trials of linaclotide. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 1, 2012. Previously presented at the Joint International Neurogastroenterology and Motility Meeting.
Forsyth B, Fehnel SE, Danchenko N, François C, Brevig T. Patient-reported cognitive symptoms and a patient-reported outcome measure of cognitive function in depression. Poster presented at the Annual European College of Neuropsychopharmacology Congress; October 1, 2012.
Baird M, Carson R, Coon CD, Fehnel SE, MacDougall J, Nelson LM, Williams VS. Psychometric validation of patient-reported outcome measures assessing chronic constipation symptom severity: results from phase 2b and phase 3 trials of linaclotide. Poster presented at the ISOQOL 19th Annual Conference; October 2012.
Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Carson RT, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing chronic constipation symptom severity and change: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 6; 24(Suppl. s2):180.
Williams VSL, Nelson LM, Carson RT, Baird MJ, Coon CD, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBS-C): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Presented at the 2012 ACG Annual Meeting and Postgraduate Course; September 1, 2012. Previously presented at the Joint International Neurogastroenterology and Motility Meeting.
Williams VS, Nelson LM, Carson RT, Baird MJ, Coon CD, Fehnel SE. Factor analyses of patient-reported outcome measures in irritable bowel syndrome with constipation (IBS-C): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 1, 2012.
Nelson LM, Williams VSL, Carson RT, Baird MJ, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBSC): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):106. doi: 10.1111/j.1365-2982.2012.01997.x
Nelson LM, Williams VS, Carson RT, Baird MJ, Coon CD, Fehnel SE. Factor analyses of chronic constipation patient-reported outcome measures: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 1, 2012.
Carson RT, Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):179.
Norquist JM, Girman C, Fehnel S, DeMuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res. 2012 Aug 1;21(6):1016-20.
Brown TM, Olanrewaju B, Deal L, Katz EC, Chiou C, Martin S, Fehnel S. Assessing pruritus among patients with atopic dermatitis: targeted literature and instrument review. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. [abstract] Value Health. 2012 Jun; 15(4):A253.
DeMuro C, Clark M, Mordin M, Fehnel S, Copley-Merriman C, Gnanasakthy A. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and niologic license applications, 2006-2010. Value Health. 2012 May 1;15(3):443-8.
Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012 May;15(3):437-42. doi: 10.1016/j.jval.2011.11.032
Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK. The development of a survey to measure completeness of response to migraine therapy. Headache. 2012 Apr 1;52(4):550-72.
DeMuro CJ, Lewis SA, DiBenedetti DB, Price MA, Fehnel SE. Successful implementation of cognitive interviews in special populations. Expert Rev Pharmacoecon Outcomes Res. 2012 Apr 1;12(2):181-7.
DiBenedetti DB, Danchenko N, Francois C, Lewis SA, Davis KH, Fehnel SE. Development of a family functioning scale for major depressive disorder. Curr Med Res Opin. 2012 Mar 1;28(3):303-13.
Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther. 2005 Dec 1;22(11-12):1162-3.
Hill CD, Fehnel SE, Hogue SL. Patient-perceived differences among commonly used antidepressants: a web-based survey. Poster presented at the US Psychiatric & Mental Health Congress; November 1, 2005.
Fehnel S, McLeod LD, Edin HM, Hogue SL. Psychometric evaluation of the motivation and energy inventory – short form (MEI-SF). Poster presented at the 12th Annual Conference of the International Society for Quality of Life Research; October 22, 2005. San Francisco, CA.
Williams V, Morlock R, Fehnel S, Wills MM, Hill CD, Barrows S, Cappelleri J, Feltner D. Development and evaluation of the daily assessment of symptoms–anxiety (DAS-A) scale for measurement of onset of symptom relief in patients with gad. Poster presented at the 12th Annual Conference of the International Society for Quality of Life Research; October 19, 2005. San Francisco, CA.
Britt DM, Fehnel SE, Granger AL, Zhou X, Williams R. Quality of life and the prevalence of vasomotor symptoms in a population-based sample of peri- and post-menopausal women. Poster presented at the 12th Annual Conference of the International Society for Quality of Life Research; October 19, 2005. San Francisco, CA.
McLeod LD, Fehnel SE, Willis MM, Hamm LR, Gilchrist KA. Psychometric validation of a patient-reported instrument assessing functional status in bipolar disorder. Poster presented at the 12th Annual Conference of the International Society for Quality of Life Research; October 19, 2005. San Francisco, CA.
Fehnel SE, Edin HM, McLeod LD, Hogue SL. Development and preliminary psychometric evaluation of the motivation and energy inventory – short form (MEI-SF). Poster presented at the 18th Congress of the European College of Neuropsychopharmacology; October 2005. Previously presented at the ISOQOL 2004 Symposium.
DiBenedetti DB, Barrett AM, Fehnel SE, Downs KE. The humanistic impact of oral anti-diabetic agents: patients' perspectives. Poster presented at the 65th American Diabetes Association; June 2005.